Effect of Benaglutide on Gut Microbiota and Fecal Metabolites in Patients with Type 2 Diabetes Mellitus

References

• Sililas P, Huang L, Thonusin C, et al. Association between gut microbiota and development of gestational diabetes mellitus. Microorganisms. 2021;9:1686. doi:10.3390/microorganisms9081686
   PubMed Web of Science ®Google Scholar
• Li SC, Xiao Y, Wu RT, et al. Comparative analysis of type 2 diabetes-associated gut microbiota between Han and Mongolian people. J Microbiol. 2021;59:693–701. doi:10.1007/s12275-021-0454-8
   PubMed Web of Science ®Google Scholar
• Maskarinec G, Raquinio P, Kristal BS, et al. The gut microbiome and type 2 diabetes status in the Multiethnic Cohort. PLoS One. 2021;16:e0250855. doi:10.1371/journal.pone.0250855
   PubMed Web of Science ®Google Scholar
• Padakandla SR, Das T, Sai Prashanthi G, et al. Dysbiosis in the gut microbiome in streptozotocin-induced diabetes rats and follow-up during retinal changes. Invest Ophthalmol Vis Sci. 2021;62:31. doi:10.1167/iovs.62.10.31
   PubMed Web of Science ®Google Scholar
• Roth-Schulze AJ, Penno MAS, Ngui KM, et al. Type 1 diabetes in pregnancy is associated with distinct changes in the composition and function of the gut microbiome. Microbiome. 2021;9:167. doi:10.1186/s40168-021-01104-y
   PubMed Web of Science ®Google Scholar
• Que Y, Cao M, He J, et al. Gut bacterial characteristics of patients with type 2 diabetes mellitus and the application potential. Front Immunol. 2021;12:722206. doi:10.3389/fimmu.2021.722206
   PubMed Web of Science ®Google Scholar
• Chen Z, Radjabzadeh D, Chen L, et al. Association of insulin resistance and type 2 diabetes with gut microbial diversity: a microbiome-wide analysis from population studies. JAMA Netw Open. 2021;4:e2118811. doi:10.1001/jamanetworkopen.2021.18811
   PubMed Web of Science ®Google Scholar
• Du X, Liu J, Xue Y, et al. Alteration of gut microbial profile in patients with diabetic nephropathy. Endocrine. 2021;73:71–84. doi:10.1007/s12020-021-02721-1
   PubMed Web of Science ®Google Scholar
• Zeng Z, Guo X, Zhang J, Yuan Q, Chen S. Lactobacillus paracasei modulates the gut microbiota and improves inflammation in type 2 diabetic rats. Food Funct. 2021;12:6809–6820. doi:10.1039/d1fo00515d
   PubMed Web of Science ®Google Scholar
• van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014;221:T1–T16. doi:10.1530/JOE-13-0414
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. doi:10.1136/bmj.d7771
   PubMed Web of Science ®Google Scholar
• Wang G, Wu P, Qiu Y, et al. Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity. Arch Endocrinol Metab. 2021;65:421–427. doi:10.20945/2359-3997000000388
   PubMed Web of Science ®Google Scholar
• Zhang F, Chen Z, Wu D, et al. Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice. iScience. 2021;24:103382. doi:10.1016/j.isci.2021.103382
   PubMed Web of Science ®Google Scholar
• Nadkarni P, Chepurny OG, Holz GG. Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci. 2014;121:23–65. doi:10.1016/B978-0-12-800101-1.00002-8
   PubMed Web of Science ®Google Scholar
• Zhang YL, Zhou C, Li XF, et al. Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study. Obes Sci Pract. 2019;5:366–375. doi:10.1002/osp4.342
   PubMed Web of Science ®Google Scholar
• Lippert K, Kedenko L, Antonielli L, et al. Gut microbiota dysbiosis associated with glucose metabolism disorders and the metabolic syndrome in older adults. Benef Microbes. 2017;8:545–556. doi:10.3920/BM2016.0184
   PubMed Web of Science ®Google Scholar
• Scheithauer TPM, Rampanelli E, Nieuwdorp M, et al. Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front Immunol. 2020;11:571731. doi:10.3389/fimmu.2020.571731
   PubMed Web of Science ®Google Scholar
• Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:102590. doi:10.1016/j.ebiom.2019.11.051
   PubMed Web of Science ®Google Scholar
• Gao R, Zhu C, Li H, et al. Dysbiosis signatures of gut microbiota along the sequence from healthy, young patients to those with overweight and obesity. Obesity. 2018;26:351–361. doi:10.1002/oby.22088
   PubMed Web of Science ®Google Scholar
• Salamon D, Sroka-Oleksiak A, Kapusta P, et al. Characteristics of gut microbiota in adult patients with type 1 and type 2 diabetes based on next‑generation sequencing of the 16S rRNA gene fragment. Pol Arch Intern Med. 2018;128:336–343. doi:10.20452/pamw.4246
   PubMedGoogle Scholar
• Tong X, Xu J, Lian F, et al. Structural alteration of gut microbiota during the amelioration of human type 2 diabetes with hyperlipidemia by metformin and a traditional Chinese herbal formula: a multicenter, randomized, open label clinical trial. mBio. 2018;9:e02392–e023117. doi:10.1128/mBio.02392-17
   PubMed Web of Science ®Google Scholar
• Murphy R, Tsai P, Jüllig M, Liu A, Plank L, Booth M. Differential changes in gut microbiota after gastric bypass and sleeve gastrectomy bariatric surgery vary according to Diabetes remission. Obes Surg. 2017;27:917–925. doi:10.1007/s11695-016-2399-2
   PubMed Web of Science ®Google Scholar
• Zhang X, Shen D, Fang Z, et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One. 2013;8:e71108. doi:10.1371/journal.pone.0071108
   PubMed Web of Science ®Google Scholar
• Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498:99–103. doi:10.1038/nature12198
   PubMed Web of Science ®Google Scholar
• Remely M, Aumueller E, Merold C, et al. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene. 2014;537:85–92. doi:10.1016/j.gene.2013.11.081
   PubMed Web of Science ®Google Scholar
• Furet JP, Kong LC, Tap J, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010;59:3049–3057. doi:10.2337/db10-0253
   PubMed Web of Science ®Google Scholar
• Graessler J, Qin Y, Zhong H, et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J. 2013;13:514–522. doi:10.1038/tpj.2012.43
   PubMed Web of Science ®Google Scholar
• Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60. doi:10.1038/nature11450
   PubMed Web of Science ®Google Scholar
• Rahat-Rozenbloom S, Fernandes J, Gloor GB, Wolever TM. Evidence for greater production of colonic short-chain fatty acids in overweight than lean humans. Int J Obes. 2014;38:1525–1531. doi:10.1038/ijo.2014.46
   PubMed Web of Science ®Google Scholar
• de la Cuesta-Zuluaga J, Mueller NT, Álvarez-Quintero R, et al. Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors. Nutrients. 2018;11(1):51. doi:10.3390/nu11010051
   PubMed Web of Science ®Google Scholar
• Atak B, Aktas G, Duman TT, Erkus E, Kocak MZ, Savli H. Diabetes control could through platelet-to-lymphocyte ratio in hemograms. Rev Assoc Med Bras. 2019;65(1):38–42. doi:10.1590/1806-9282.65.1.38
   PubMed Web of Science ®Google Scholar
• Aktas G, Kocak MZ, Bilgin S, Atak BM, Duman TT, Kurtkulagi O. Uric acid to HDL cholesterol ratio is a strong predictor of diabetic control in men with type 2 diabetes mellitus. Aging Male. 2020;23(5):1098–1102. doi:10.1080/13685538.2019.1678126
   PubMed Web of Science ®Google Scholar
• Aktas G, Kocak MZ, Duman TT,et al. Mean Platelet Volume (MPV) as an inflammatory marker in type 2 diabetes mellitus and obesity. Bali Med J. 2018;7(3):650–953. doi:10.15562/bmj.v7i3.806
   Web of Science ®Google Scholar
• Brennan CA, Garrett WS. Gut microbiota, inflammation, and colorectal cancer. Annu Rev Microbiol. 2016;70:395–411. doi:10.1146/annurev-micro-102215-095513
   PubMed Web of Science ®Google Scholar
• Nøhr MK, Pedersen MH, Gille A, et al. GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology. 2013;154:3552–3564. doi:10.1210/en.2013-1142
   PubMed Web of Science ®Google Scholar
• Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61:364–371. doi:10.2337/db11-1019
   PubMed Web of Science ®Google Scholar
• Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15:1546–1558. doi:10.2174/138161209788168164
   PubMed Web of Science ®Google Scholar
• Brønden A, Christensen MB, Glintborg D, et al. Effects of DPP −4 inhibitors, GLP −1 receptor agonists, SGLT −2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: a network meta-analyses-driven approach. Diabet Med. 2023;40:e15157. doi:10.1111/dme.15157
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742. doi:10.1038/nrendo.2012.140
   PubMed Web of Science ®Google Scholar